File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies

TitleOptimal stem cell source for allogeneic stem cell transplantation for hematological malignancies
Authors
KeywordsHematopoietic stem cell transplantation
Bone marrow
Peripheral blood stem cell
Cord blood
Hematological malignancy
Issue Date2013
PublisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/2218-6204/index.htm
Citation
World Journal of Transplantation, 2013, v. 3 n. 4, p. 99-112 How to Cite?
AbstractHematopoietic stem cell transplant (HSCT) is a standard treatment for many hematological malignancies. Three different sources of stem cells, namely bone marrow (BM), peripheral blood stem cells (PBSC) and cord blood (CB) can be used for HSCT, and each has its own advantages and disadvantages. Randomized controlled trials (RCTs) suggest that there is no significant survival advantage of PBSC over BM in Human Leukocyte Antigen-matched sibling transplant for adult patients with hematological malignancies. PBSC transplant probably results in lower risk of relapse and hence better disease-free survival, especially in patients with high risk disease at the expense of higher risks of both severe acute and chronic graft-versus-host disease (GVHD). In the unrelated donor setting, the only RCT available suggests that PBSC and BM result in comparable overall and disease-free survivals in patients with hematological malignancies; and PBSC transplant results in lower risk of graft failure and higher risk of chronic GVHD. High level evidence is not available for CB in comparison to BM or PBSC. The risks and benefits of different sources of stem cells likely change with different conditioning regimen, strategies for prophylaxis and treatment of GVHD and manipulation of grafts. The recent success and rapid advance of double CB transplant and haploidentical BM and PBSC transplants further complicate the selection of stem cell source. Optimal selection requires careful weighing of the risks and benefits of different stem cell source for each individual recipient and donor. Detailed counseling of patient and donor regarding risks and benefits in the specific context of the patient and transplant method is essential for informed decision making.
Persistent Identifierhttp://hdl.handle.net/10722/197619
ISSN
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorCheuk, DKLen_US
dc.date.accessioned2014-05-29T08:31:44Z-
dc.date.available2014-05-29T08:31:44Z-
dc.date.issued2013en_US
dc.identifier.citationWorld Journal of Transplantation, 2013, v. 3 n. 4, p. 99-112en_US
dc.identifier.issn2218-6204-
dc.identifier.urihttp://hdl.handle.net/10722/197619-
dc.description.abstractHematopoietic stem cell transplant (HSCT) is a standard treatment for many hematological malignancies. Three different sources of stem cells, namely bone marrow (BM), peripheral blood stem cells (PBSC) and cord blood (CB) can be used for HSCT, and each has its own advantages and disadvantages. Randomized controlled trials (RCTs) suggest that there is no significant survival advantage of PBSC over BM in Human Leukocyte Antigen-matched sibling transplant for adult patients with hematological malignancies. PBSC transplant probably results in lower risk of relapse and hence better disease-free survival, especially in patients with high risk disease at the expense of higher risks of both severe acute and chronic graft-versus-host disease (GVHD). In the unrelated donor setting, the only RCT available suggests that PBSC and BM result in comparable overall and disease-free survivals in patients with hematological malignancies; and PBSC transplant results in lower risk of graft failure and higher risk of chronic GVHD. High level evidence is not available for CB in comparison to BM or PBSC. The risks and benefits of different sources of stem cells likely change with different conditioning regimen, strategies for prophylaxis and treatment of GVHD and manipulation of grafts. The recent success and rapid advance of double CB transplant and haploidentical BM and PBSC transplants further complicate the selection of stem cell source. Optimal selection requires careful weighing of the risks and benefits of different stem cell source for each individual recipient and donor. Detailed counseling of patient and donor regarding risks and benefits in the specific context of the patient and transplant method is essential for informed decision making.-
dc.languageengen_US
dc.publisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/2218-6204/index.htm-
dc.relation.ispartofWorld Journal of Transplantationen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectHematopoietic stem cell transplantation-
dc.subjectBone marrow-
dc.subjectPeripheral blood stem cell-
dc.subjectCord blood-
dc.subjectHematological malignancy-
dc.titleOptimal stem cell source for allogeneic stem cell transplantation for hematological malignanciesen_US
dc.typeArticleen_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.5500/wjt.v3.i4.99-
dc.identifier.pmid24392314-
dc.identifier.pmcidPMC3879529-
dc.identifier.hkuros229012en_US
dc.identifier.volume3en_US
dc.identifier.issue4en_US
dc.identifier.spage99en_US
dc.identifier.epage112en_US
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats